(Q38475793)

English

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

scientific article published on 20 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

3 September 2017

0 references

Antonio Bruno

1

0 references

Gianluca Pandolfo

Gianluca Pandolfo

3

0 references

Maria Rosaria Anna Muscatello

Maria Rosaria A Muscatello

10

0 references

Edoardo Spina

8

0 references

author name string

Umberto Micò

2

1 reference

Europe PubMed Central

3 September 2017

Domenico Mallamace

4

1 reference

Europe PubMed Central

3 September 2017

Elisabetta Abenavoli

5

1 reference

Europe PubMed Central

3 September 2017

Floriana Di Nardo

6

1 reference

Europe PubMed Central

3 September 2017

Concetta D'Arrigo

7

1 reference

Europe PubMed Central

3 September 2017

Rocco A Zoccali

9

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

20 February 2012

1 reference

Europe PubMed Central

3 September 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

3 September 2017

26

1 reference

Europe PubMed Central

3 September 2017

1456-1462

1 reference

Europe PubMed Central

3 September 2017

11

1 reference

Europe PubMed Central

3 September 2017

A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Glutamatergic dysfunction in OCD.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

A review of antipsychotics in the treatment of obsessive compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

The Yale-Brown Obsessive Compulsive Scale. II. Validity.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Altered cortical excitability in obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Lamotrigine update and its use in mood disorders.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Quality of life in obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Advances in the treatment of anxiety: targeting glutamate.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881111431751

21 January 2018

Identifiers

10.1177/0269881111431751

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38475793&oldid=1026212211"